Mark A. Levy, Ph.D. Co-Founder & Consultant, HEN-MAR
Mark has had more than 25 years of extensive experience integrating preclinical biochemical, chemical, and ADME (absorption, disposition, metabolism, elimination) properties of experimental molecules across the Discovery (compound-identification) and Development (compound-progression) phases of the R&D process. He has contributed to several successful NDAs / MAAs (Altabax, Volibris, Promacta) and over 35 INDs related to new chemical entities.
Most recently Mark was Site Director of Preclinical Drug Metabolism and Pharmacokinetics (DMPK) at GlaxoSmithKline’s (GSK’s) Upper Merion, PA site. In this role he led a scientific group characterizing the ADME of development molecules from several Centers of Excellence for Drug Discovery (CEDDs) covering a range of therapeutic areas (cardiovascular, urology, antibacterial, antifungal, oncology, topical, ocular) and provided expertise for evaluating in- and out-licensing ventures and management of collaborative partnerships. He was active in the DMPK Department worldwide management team and represented GSK on the Drug Metabolism Technical Group (DMTG) PhRMA advisory committee for over 4 years. Prior to the formation of GSK, Mark was Worldwide Director of Discovery DMPK at SmithKline Beecham (SB), having also led Discovery Teams and being responsible for potency and efficacy characterization of novel enzyme inhibitors within Discovery efforts.
Mark has a B.A. degree (summa cum laude) in Chemistry from Washington University, St. Louis, MO with an M.S. in Chemistry and Ph.D. in Bio-Organic Chemistry from Northwestern University, Evanston, IL. Prior to joining the pharmaceutical industry he was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology, Cambridge, MA. Mark has authored / co-authored over 120 manuscripts, posters and abstracts, and is cited as co-inventor on over 30 issued US and European patents.
